An extrapolation of MEDIPHARM LABS' 50-day and 200-day moving average lines suggests a GOLDEN CROSS should take place early next year.
According to The Globe and Mail, the target price for LABS is $0.10:
https://www.theglobeandmail.com/investing/markets/stocks/LABS-T/research/
This represents a 20% upside potential.
GLTA!
According to The Globe and Mail, the target price for LABS is $0.10:
https://www.theglobeandmail.com/investing/markets/stocks/LABS-T/research/
This represents a 20% upside potential.
GLTA!
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。